The diagnosis of primary biliary cirrhosis

Autoimmunity Reviews

Volumn 13, Issue 4-5, 2014, Pages 441-444

  Bowlus, Christopher L ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti mitochondrial antibody; Anti nuclear antibody; Diagnosis; Epidemiology; Primary biliary cirrhosis

Indexed keywords

ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CHOLESTASIS; CLINICAL FEATURE; DISEASE COURSE; EPITHELIUM CELL; FATIGUE; HUMAN; INCIDENCE; INTRAHEPATIC BILE DUCT; LIVER CIRRHOSIS; LIVER HISTOLOGY; MORBIDITY; NONHUMAN; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRURITUS; RARE DISEASE; REVIEW; RISK FACTOR; T LYMPHOCYTE;

ANTI-MITOCHONDRIAL ANTIBODY; ANTI-NUCLEAR ANTIBODY; DIAGNOSIS; EPIDEMIOLOGY; PRIMARY BILIARY CIRRHOSIS;

ANIMALS; ANTIBODIES; DIAGNOSIS, DIFFERENTIAL; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; MITOCHONDRIA;

EID: 84896318838     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.01.041     Document Type: Review

References (65)

1. Dahlan Y., Smith L., Simmonds D., Jewell L.D., Wanless I., Heathcote E.J., et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003, 125:1476-1479.
2. Kim W.R., Lindor K.D., Locke G.R., Therneau T.M., Homburger H.A., Batts K.P., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119:1631-1636.
3. Sood S., Gow P.J., Christie J.M., Angus P.W. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology 2004, 127:470-475.
4. Mattalia A., Quaranta S., Leung P.S., Bauducci M., Van de Water J., Calvo P.L., et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998, 27:656-661.
5. Selmi C., Invernizzi P., Zuin M., Podda M., Gershwin M.E. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis 2005, 25:265-280.
6. Pla X., Vergara M., Gil M., Dalmau B., Cistero B., Bella R.M., et al. Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. Eur J Gastroenterol Hepatol 2007, 19:859-864.
7. Triger D.R. Primary biliary cirrhosis: an epidemiological study. Br Med J 1980, 281:772-775.
8. Ray-Chadhuri D., Rigney E., MacComack K. Epidemiology of PBC in Sheffield updated: demographics and relation to water supply. Gut 2001, 48:42.
9. Myszor M., James O.F. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease?. Q J Med 1990, 75:377-385.
10. James O.F., Bhopal R., Howel D., Gray J., Burt A.D., Metcalf J.V. Primary biliary cirrhosis once rare, now common in the United Kingdom?. Hepatology 1999, 30:390-394.
11. Lleo A., Battezzati P.M., Selmi C., Gershwin M.E., Podda M. Is autoimmunity a matter of sex?. Autoimmun Rev 2008, 7:626-630.
12. Burroughs A.K., Rosenstein I.J., Epstein O., Hamilton-Miller J.M., Brumfitt W., Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984, 25:133-137.
13. Gershwin M.E., Selmi C., Worman H.J., Gold E.B., Watnik M., Utts J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
14. Prince M.I., Ducker S.J., James O.F. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut 2010, 59:508-512.
15. Ala A., Stanca C.M., Bu-Ghanim M., Ahmado I., Branch A.D., Schiano T.D., et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology 2006, 43:525-531.
16. McNally R.J., Ducker S., James O.F. Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis. Hepatology 2009, 50:1169-1174.
17. Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
18. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
19. Walker J.G., Doniach D., Roitt I.M., Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1965, 39:827-831.
20. Gershwin M.E., Mackay I.R., Sturgess A., Coppel R.L. Identification and specificity of a cDNA encoding the 70kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987, 138:3525-3531.
21. Fussey S.P., Guest J.R., James O.F., Bassendine M.F., Yeaman S.J. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci U S A 1988, 85:8654-8658.
22. Mutimer D.J., Fussey S.P., Yeaman S.J., Kelly P.J., James O.F., Bassendine M.F. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 1989, 10:403-407.
23. Cha S., Leung P.S., Gershwin M.E., Fletcher M.P., Ansari A.A., Coppel R.L. Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis. Proc Natl Acad Sci U S A 1993, 90:2527-2531.
24. Invernizzi P., Crosignani A., Battezzati P.M., Covini G., De Valle G., Larghi A., et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997, 25:1090-1095.
25. Invernizzi P., Selmi C., Ranftler C., Podda M., Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005, 25:298-310.
26. Wesierska-Gadek J., Penner E., Battezzati P.M., Selmi C., Zuin M., Hitchman E., et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006, 43:1135-1144.
27. Nakamura M., Kondo H., Mori T., Komori A., Matsuyama M., Ito M., et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007, 45:118-127.
28. Ludwig J., Dickson E.R., McDonald G.S. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978, 379:103-112.
29. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967, 60:1257-1260.
30. Chazouilleres O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
31. Silveira M.G., Talwalkar J.A., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007, 102:1244-1250.
32. Telesca D., Etzioni R., Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008, 64:10-19.
33. Lee J., Belanger A., Doucette J.T., Stanca C., Friedman S., Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007, 5:1313-1315.
34. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001, 33:22-27.
35. Prince M., Chetwynd A., Newman W., Metcalf J.V., James O.F. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28years. Gastroenterology 2002, 123:1044-1051.
36. Springer J., Cauch-Dudek K., O'Rourke K., Wanless I.R., Heathcote E.J. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999, 94:47-53.
37. Dickson E.R., Grambsch P.M., Fleming T.R., Fisher L.D., Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989, 10:1-7.
38. Huet P.M., Vincent C., Deslaurier J., Cote J., Matsutami S., Boileau R., et al. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology 2008, 135:1552-1560.
39. Poupon R.E., Lindor K.D., Cauch-Dudek K., Dickson E.R., Poupon R., Heathcote E.J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884-890.
40. Corpechot C., Carrat F., Bahr A., Chretien Y., Poupon R.E., Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128:297-303.
41. Pares A., Caballeria L., Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006, 130:715-720.
42. van Hoogstraten H.J., Hansen B.E., van Buuren H.R., ten Kate F.J., van Berge-Henegouwen G.P., Schalm S.W. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. J Hepatol 1999, 31:256-262.
43. Kuiper E.M., Hansen B.E., de Vries R.A., den Ouden-Muller J.W., van Ditzhuijsen T.J., Haagsma E.B., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136:1281-1287.
44. Kumagi T., Guindi M., Fischer S.E., Arenovich T., Abdalian R., Coltescu C., et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010, 105:2186-2194.
45. Carbone M., Mells G.F., Pells G., Dawwas M.F., Newton J.L., Heneghan M.A., et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013, 144:560-569. [e7; quiz e13-4].
46. Kaplan M.M., Bonder A., Ruthazer R., Bonis P.A. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci 2010, 55:3207-3217.
47. Giljaca V., Poropat G., Stimac D., Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 2010, CD004385.
48. Combes B., Emerson S.S., Flye N.L., Munoz S.J., Luketic V.A., Mayo M.J., et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005, 42:1184-1193.
49. Mason A., Luketic V., Hirschfield G., Gordon S., Mayo M., et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 (obeticholic acid) to ursodeoxycholic acid. J Hepatol 2010, 52:S1.
50. Myers R.P., Swain M.G., Lee S.S., Shaheen A.A., Burak K.W. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 2013, 108:933-941.
51. Tsuda M., Moritoki Y., Lian Z.X., Zhang W., Yoshida K., Wakabayashi K., et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012, 55:512-521.
52. Leung P.S., Yang G.X., Dhirapong A., Tsuneyama K., Ridgway W.M., Gershwin M.E. Animal models of primary biliary cirrhosis: materials and methods. Methods Mol Biol 2012, 900:291-316.
53. Dhirapong A., Yang G.X., Nadler S., Zhang W., Tsuneyama K., Leung P., et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 2013, 57:708-715.
54. Henao-Mejia J., Elinav E., Thaiss C.A., Licona-Limon P., Flavell R.R. Role of theintestinal microbiome in liver disease. J Autoimmun 2013, 46:66-73.
55. Invernizzi P. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. J Autoimmun 2013, 46:1-6. [2013 Sep 5. PubMed PMID: 24012346].
56. Mells G.F., Kaser A., Karlsen T.H. Novel insights into autoimmune liver diseasesprovided by genome-wide association studies. J Autoimmun 2013, 46:41-54.
57. Trivedi P.J., Adams D.H. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 2013, 46:97-111.
58. Podda M., Selmi C., Lleo A., Moroni L., Invernizzi P. The limitations and hiddengems of the epidemiology of primary biliary cirrhosis. J Autoimmun 2013, 46:81-87.
59. Imam M.H., Talwalkar J.A., Lindor K.D. Clinical management of autoimmune biliarydiseases. J Autoimmun 2013, 46:88-96.
60. Leung P.S., Wang J., Naiyanetr P., Kenny T.P., Lam K.S., Kurth M.J., et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun 2013, 41:79-86.
61. Wang Q., Selmi C., Zhou X., Qiu D., Li Z., Miao Q., et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 2013, 41:140-145.
62. + T cells, and development of autoimmune cholangitis in dnTGFβRII mice. Hepatology 2013, 58:1094-1104.
63. Tsuda M., Zhang W., Yang G.X., Tsuneyama K., Ando Y., Kawata K., et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology 2013, 57:806-816.
64. Ando Y., Yang G.X., Tsuda M., Kawata K., Zhang W., Nakajima T., et al. The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology 2012, 56:1418-1426.
65. Chen R.C., Naiyanetr P., Shu S.A., Wang J., Yang G.X., Kenny T.P., et al. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 2013, 57:1498-1508.